ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer
ORIC Pharmaceuticals (Nasdaq: ORIC) has appointed Kevin Brodbeck, PhD as its first Chief Technical Officer (CTO), strengthening its leadership team ahead of potential Phase 3 trials in 2026. Dr. Brodbeck brings over 25 years of experience in technical operations, quality assurance, and CMC activities.
The strategic appointment comes as ORIC prepares for late-stage development of two key programs: ORIC-944 and enozertinib (ORIC-114). Dr. Brodbeck's previous roles include Chief Technical and Development Operations Officer at Deciphera Pharmaceuticals and SVP of Technical Operations at Nektar Therapeutics, where he led various development programs and managed global CMC operations.
ORIC Pharmaceuticals (Nasdaq: ORIC) ha nominato Kevin Brodbeck, PhD come suo primo Chief Technical Officer (CTO), rafforzando il team dirigenziale in vista di possibili trial di Fase 3 nel 2026. Il dott. Brodbeck vanta oltre 25 anni di esperienza in operazioni tecniche, assurance della qualità e attività CMC.
La nomina strategica avviene mentre ORIC si prepara per lo sviluppo in fase avanzata di due programmi chiave: ORIC-944 ed enozertinib (ORIC-114). Tra i precedenti incarichi del dott. Brodbeck figurano Chief Technical and Development Operations Officer presso Deciphera Pharmaceuticals e SVP of Technical Operations presso Nektar Therapeutics, dove ha guidato diversi programmi di sviluppo e gestito le operazioni CMC a livello globale.
ORIC Pharmaceuticals (Nasdaq: ORIC) ha nombrado a Kevin Brodbeck, PhD como su primer Chief Technical Officer (CTO), reforzando su equipo directivo de cara a posibles ensayos de Fase 3 en 2026. El Dr. Brodbeck aporta más de 25 años de experiencia en operaciones técnicas, aseguramiento de la calidad y actividades CMC.
El nombramiento estratégico se produce mientras ORIC se prepara para el desarrollo en fase avanzada de dos programas clave: ORIC-944 y enozertinib (ORIC-114). Entre los cargos previos del Dr. Brodbeck se incluyen Chief Technical and Development Operations Officer en Deciphera Pharmaceuticals y SVP of Technical Operations en Nektar Therapeutics, donde lideró varios programas de desarrollo y gestionó operaciones CMC a nivel global.
ORIC Pharmaceuticals (Nasdaq: ORIC)는 Kevin Brodbeck, PhD를 초대 최고기술책임자(CTO)로 임명하여 2026년 예상되는 3상 시험을 앞두고 경영진을 강화했습니다. Brodbeck 박사는 기술 운영, 품질 보증 및 CMC 업무에서 25년 이상의 경험을 보유하고 있습니다.
이번 전략적 임명은 ORIC가 두 가지 주요 프로그램인 ORIC-944와 enozertinib (ORIC-114)의 후기 개발을 준비하는 가운데 이뤄졌습니다. Brodbeck 박사는 이전에 Deciphera Pharmaceuticals의 Chief Technical and Development Operations Officer 및 Nektar Therapeutics의 SVP of Technical Operations를 역임하며 여러 개발 프로그램을 이끌고 전 세계 CMC 운영을 관리했습니다.
ORIC Pharmaceuticals (Nasdaq: ORIC) a nommé Kevin Brodbeck, PhD comme premier Chief Technical Officer (CTO), renforçant son équipe dirigeante en vue d'éventuels essais de phase 3 en 2026. Le Dr Brodbeck apporte plus de 25 ans d'expérience en opérations techniques, assurance qualité et activités CMC.
Cette nomination stratégique intervient alors qu'ORIC se prépare au développement en phase avancée de deux programmes clés : ORIC-944 et enozertinib (ORIC-114). Parmi les précédents postes du Dr Brodbeck figurent Chief Technical and Development Operations Officer chez Deciphera Pharmaceuticals et SVP of Technical Operations chez Nektar Therapeutics, où il a dirigé divers programmes de développement et géré les opérations CMC à l'échelle mondiale.
ORIC Pharmaceuticals (Nasdaq: ORIC) hat Kevin Brodbeck, PhD als ersten Chief Technical Officer (CTO) berufen und verstärkt damit die Geschäftsführung im Vorfeld möglicher Phase‑3‑Studien im Jahr 2026. Dr. Brodbeck bringt über 25 Jahre Erfahrung in technischen Abläufen, Qualitätssicherung und CMC‑Aktivitäten mit.
Die strategische Ernennung erfolgt, während ORIC sich auf die späte Entwicklungsphase zweier Schlüsselprogramme vorbereitet: ORIC‑944 und enozertinib (ORIC‑114). Zu Dr. Brodbecks früheren Positionen zählen Chief Technical and Development Operations Officer bei Deciphera Pharmaceuticals und SVP of Technical Operations bei Nektar Therapeutics, wo er verschiedene Entwicklungsprogramme leitete und globale CMC‑Operationen verantwortete.
- Strategic appointment ahead of potential Phase 3 trials for two drug candidates in 2026
- Addition of highly experienced executive with 25+ years in technical operations and CMC
- Strengthening of leadership team signals preparation for late-stage development and potential commercialization
- Company still in clinical stage with no commercialized products
- Phase 3 trials yet to begin, indicating significant time and investment needed before potential commercialization
Insights
ORIC's new CTO appointment signals preparation for Phase 3 trials of two oncology candidates in 2026, strengthening late-stage development capabilities.
ORIC Pharmaceuticals has strategically created a new Chief Technical Officer position and appointed Kevin Brodbeck, PhD, a veteran with 25+ years of experience in technical operations and CMC. This move explicitly telegraphs the company's progression toward late-stage clinical development, with management highlighting the potential initiation of Phase 3 trials for two lead candidates (ORIC-944 and enozertinib) in 2026.
Dr. Brodbeck's background is particularly relevant for a clinical-stage company approaching pivotal trials. His experience at Deciphera included expanding Qinlock internationally and preparing Romvimza for regulatory approval in major markets. At Nektar Therapeutics, he led development programs across multiple therapeutic areas and stages, suggesting he brings valuable expertise in navigating the complex technical requirements for late-stage clinical development and commercialization.
This appointment represents more than routine personnel changes—it's a structural adaptation as ORIC transitions from a primarily early/mid-stage clinical company toward potential commercialization. The creation of this role signals management's focus on building infrastructure for manufacturing, quality control, and regulatory compliance required for registrational trials and beyond. For clinical-stage biotechs, this preparation phase is critical, as technical operations failures can lead to significant delays in the approval pathway even when clinical data is positive.
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Kevin Brodbeck, PhD, to the newly established role of Chief Technical Officer (CTO). Dr. Brodbeck brings more than 25 years of experience leading technical operations, quality assurance, chemistry, manufacturing and controls (CMC), and regulatory activities across a wide range of pharmaceutical products at all stages of development and commercialization. The creation of the CTO role and Dr. Brodbeck’s appointment reflect the impending advancement of ORIC’s clinical programs into late-stage development with the potential start of Phase 3 trials for ORIC-944 and enozertinib (ORIC-114) in 2026.
“We are excited to welcome Kevin to the ORIC leadership team,” said Jacob M. Chacko, MD, president, and chief executive officer. “As we approach the potential initiation of Phase 3 trials next year for ORIC-944 and enozertinib, CMC and Technical Operations will become increasingly critical, and we have been fortunate to identify in Kevin a seasoned leader with a multi-decade experience leading these critical functions.”
Dr. Brodbeck was previously the Chief Technical and Development Operations Officer at Deciphera Pharmaceuticals where he led Pharmaceutical Sciences (CMC), Supply Chain, Clinical Operations, and Program Management functions, and co-led the strategic portfolio governance for the company. In his tenure at Deciphera through its acquisition by Ono and afterwards, he worked to expand Qinlock® internationally, readied Romvimza™ for approval and launch in the US and EU and established strategic partnerships with commercial manufacturing and development organizations. Prior to joining Deciphera, he served as SVP of Technical Operations at Nektar Therapeutics where he led development programs in oncology, immunotherapy, anti-infective, and pain, ranging from early development to commercial. While at Nektar, he led the global CMC development and manufacturing organization consisting of product and process development, analytical sciences, internal and external manufacturing, quality assurance and control, and supply chain management. He served as the Chair of the Board for Nektar, India LLP and held multiple product development leadership positions at ALZA and Powderject. Dr. Brodbeck has a PhD in Chemical Engineering from University of Illinois, Urbana-Champaign, and a BS in Chemical Engineering from the University of California, Berkeley.
“I’m thrilled to join ORIC as the company makes this pivotal transition into late-stage development,” said Dr. Brodbeck. “I look forward to working with the entire ORIC team to prepare for the potential start of multiple registrational trials next year and the eventual commercialization of innovative therapies that address cancer resistance to improve patients’ lives.”
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib (ORIC-114), a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the continued clinical development of ORIC-944 and enozertinib (formerly ORIC-114); the potential advantages of ORIC-944 and enozertinib; the development plans and timelines for ORIC-944 and enozertinib; plans underlying ORIC’s clinical trials and development; anticipated program milestones, including timing of initiation of registrational trials; and statements by the company’s chief technical officer and chief executive officer. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC’s plans to develop and commercialize its product candidates; the potential for clinical trials of ORIC-944, enozertinib or any other product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC’s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC’s license and collaboration agreements or its clinical trial collaboration and supply agreements; the potential market for ORIC’s product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC’s reliance on third parties, including contract manufacturers and contract research organizations; ORIC’s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in ORIC’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the SEC) on August 12, 2025, and ORIC’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
FAQ
Who is ORIC Pharmaceuticals' new Chief Technical Officer?
What are ORIC's main drug candidates moving to Phase 3 trials?
What is Kevin Brodbeck's previous experience before joining ORIC?
Why did ORIC Pharmaceuticals create the CTO position?
What type of company is ORIC Pharmaceuticals?
